Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study

Takimoto, Rishu; Kamigaki, Takashi; Okada, Sachiko; Matsuda, Eriko; Ibe, Hiroshi; Oguma, Eri; Naitoh, Keiko; Makita, Kaori; Goto, Shigenori

doi:10.21873/anticanres.13629

Cited by 8 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of chemotherapeutic agents, such as cisplatin, with ACT has been reported to improve the survival time of patients with cervical cancer (17). In the comparison between immune-cell therapy alone and immune-cell therapy combined with other treatments, several studies have demonstrated that combination therapy shows better therapeutic effects than immune-cell therapy alone (16,(18)(19)(20)(21). In our study, the combination of immune-cell therapy and chemotherapy did not provide any survival benefit for advanced or recurrent endometrial and cervical cancer patients, although the MST of these patients treated with a combination of immune-cell therapy and chemotherapy was longer than that of the historical control.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study

Takimoto

Kamigaki

Okada³

et al. 2020

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: In this retrospective study, we aimed to investigate the efficacy of immune-cell therapy using T lymphocytes activated in vitro with or without dendritic cell vaccination in combination with standard therapies in terms of the survival of patients with advanced or recurrent endometrial and cervical cancers of the uterus. Patients and Methods: A total of 187 patients with advanced or recurrent uterine cancer were enrolled in this study. The correlation between overall survival and various clinical factors was examined by univariate and multivariate analyses. Results: Univariate analysis revealed that the prognosis was improved in uterine cancer patients who received immune-cell therapy without prior chemotherapy or without distant metastasis. Multivariate analysis demonstrated that the absence of prior chemotherapy for endometrial cancer and liver/lung metastasis of cervical cancer are indications for immune-cell therapy. Conclusion: Survival benefit in uterine cancer patients could be potentially obtained by a combination of immune-cell therapy with other therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Adoptive immune-cell therapy is still under evaluation for use in advanced endometrial cancer, as in many other malignancies (16,20,21), but the more mature data available are about the checkpoint inhibitors. The PD-L1 expression levels in endometrial cancer have been estimated to be 67-100% (23).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study

Takimoto

Kamigaki

Okada³

et al. 2020

Anticancer Res

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) is the third most commonly detected cancer with 1.8 million cases worldwide in 2018 [1][2][3]. Currently, conventional treatments for CRC include surgical removal of tumors, radiation therapy, and chemotherapy [4]. Despite advances in these treatments, CRC has shown resistance to these treatments alone [5].…”

Section: Introductionmentioning

confidence: 99%

Transcriptional Regulation of the Colorectal Cancer Stem Cell Markers, Nanog and Oct4, Induced by a Thermodynamic-Based Therapy Approach

Ghorbani

Heidari

Jafarinia

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Cancer stem cells (CSC) play a crucial role in tumorigenesis, recurrence, metastasis, and chemoresistanc. Some studies suggest that hyperthermia and photodynamic therapy (PDT) may be effective for cancer treatment, particularly when combined with other therapeutic approaches. However, the results are conflicting. Our aim was to evaluate the effect of hyperthermia combined with PDT on colorectal CSC viability and the gene expression of the CSC markers.Results: Cell viability decrased by PDT (P=0.015) and the combination therapy (P=0.006) but not hyperthermia alone (P=0.4) compared to control. Gene expression of CSC markers significantly decreased in all therapies. Conclusion: Hyperthermia combined with PDT was more efficient in eliminating tumors than hyperthermia or PDT alone.

show abstract

“…as a combination between chemotherapy and immunotherapy, has been developed as a more powerful anticancer therapy. Accumulating evidence sheds light on chemoimmunotherapy using adoptive T cell transfusions as a useful mCRC therapy (19)(20)(21)(22). Previously, we showed that chemoimmunotherapy using αβ T cells was feasible and safe in stage IV CRC (22,23).…”

mentioning

confidence: 99%

Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy

et al. 2020

View full text Add to dashboard Cite

Background/Aim: Chemoimmunotherapy is a promising treatment for various malignant diseases. In this study, we examined whether first-line chemoimmunotherapy using adoptive immune-cell therapy was effective for metastatic colorectal cancer (mCRC). Patients and Methods: The therapeutic efficacy and safety of the standard first-line chemoimmunotherapy with adoptive αβ T cell therapy and bevacizumab were assessed using thirty-two patients with mCRC in our hospital. Immunological status after this chemoimmunotherapy was also evaluated. Results: The response and disease control rates were 68.8% and 87.5%, respectively. Further, median progression-free and overall survival were 14.2 and 35.3 months. Immunotherapyassociated toxicity was minimal. Significant decrease in the change of monocyte number (p=0.006) and increase in the change of rate of lymphocyte-to-monocyte ratio (p=0.039) were seen in the complete response group. Conclusion: Firstline chemoimmunotherapy with adoptive αβ T cell therapy may be useful for mCRC.Colorectal cancer (CRC) is one of the major malignant diseases in Japan (1). Chemotherapy is one of the effective treatments for CRC, and various novel chemotherapeutic agents including oxaliplatin, irinotecan and targeted therapies have contributed to the improvement of the prognosis (2). However, the prognosis of metastatic CRC (mCRC) remains poor (3-5). Therefore, the development of a novel therapy overcoming mCRC is urgent.Recently, immunotherapy is considered as a promising therapeutic strategy for advanced cancers. In particular, blockade of T cell inhibitory checkpoint molecules can unleash anti-tumour T cell activity and lead to long-term clinical responses in patients with advanced malignant diseases including lung cancer, melanoma, and Hodgkin's disease (6-10). However, patients in mCRC rarely enjoy the benefits of the current immune checkpoint blockade regimens due to inherent tumour cell resistance or extrinsic factors restraining anti-tumour immunity (11). Therefore, establishment of further improved immunotherapy for mCRC is a pivotal challenge.Adoptive immune-cell therapy is a novel cancer immunotherapy characterized as the re-infusion of ex vivoactivated and expanded T cells, such as αβ T cells, γδ T cells and natural killer cells. It has been proposed that adoptive immune-cell therapy stimulates and restores anti-tumour immunity because it enables immune cells to recognize and terminate tumour cells (12). Additionally, this therapy has a limited toxicity profile as opposed to established chemotherapy and checkpoint blockade (13-15). Among them, ex vivoexpanded αβ T cells have been studied for their antitumor effects (16,17) and applied to treatment of some cancers including hepatocellular carcinoma (18) and lung cancer (19) in the clinical setting. Recently, chemoimmunotherapy, defined 4763

show abstract

Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study

Cited by 8 publications

References 32 publications

Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study

Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study

Transcriptional Regulation of the Colorectal Cancer Stem Cell Markers, Nanog and Oct4, Induced by a Thermodynamic-Based Therapy Approach

Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy

Contact Info

Product

Resources

About